江苏联环药业股份有限公司关于全资子公司购买资产暨关联交易的进展公告

Group 1 - The company announced the progress of an asset purchase and related party transaction involving its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd. [2] - The transaction was approved during the board meeting on September 12, 2025, and the subsequent shareholder meeting on September 30, 2025, with a purchase price of 74.5 million RMB (excluding tax) for certain buildings and land use rights [2] - Lianhuan (Anqing) has paid 50% of the transaction amount and related taxes, and has completed the necessary property rights transfer procedures, obtaining the property certificate from the Anqing Natural Resources and Planning Bureau [3]